Press Releases for NVAX

Press Releases
Stock to Watch: China Direct Industries - January 12, 2010
Analyst Choice Market Review on Companies Basic Materials and Healthcare Sectors
NOVAVAX Virus-Like Particle Vaccine Protects Against 2009 Pandemic H1N1 Influenza Virus
BenchmarkJournal.Com Free Analyst Review for CMCSK, NVAX, ARUN, CREE, XTNT and CDNS
Novavax Reports Second Quarter 2009 Financial Results
Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer
BioMed Realty Trust Commemorates Five-Year Anniversary As a Public Company ; Ringing NYSE Closing Bell(R) Today; Provides Tenant Update
NOVAVAX Achieves Pandemic H1N1 Influenza Production Milestone
StockPreacher.com Issues Trading Outlook for Novavax Inc.
Novavax Announces Release Date of 2009 Second Quarter, Financial Results and Investor Conference Call
Breaking News: SUWN - July 30, 2009
Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies
Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances
Novavax Announces Repayment of $5 Million of Convertible Debt
Cadila Pharmaceuticals Launches Joint Venture With Novavax in India
Spanish Government Selects Novavax's VLP Technology for Comprehensive Flu Vaccine Solution in Spain
Novavax Appoints Stanley Erck to Board of Directors
Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2009
Free Growth Strategy Report on PETM, QCOM, CELG and NVAX By MaybachFinancial.Com
Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
Petro Resources Announces New Management Changes
Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial
Novavax Reports First Quarter 2009 Financial Results
Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
Novavax Announces Closing of $11 Million Common Stock Sale to Subsidiary of Cadila Pharmaceuticals
Novavax Reports Fourth Quarter and 2008 Year-End Financial Results
Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus ('RSV') Vaccine Candidate Directed Against the Fusion (F) Protein
Novavax Reports Positive Preclinical Results for a Novel, Broadly Cross-Protective H5N1 Pandemic Influenza Virus-like Particle (VLP) Vaccine Candidate
Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009
Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate
NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus ('RSV') Vaccine Candidate
Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008
Novavax Announces Preclinical Data for Respiratory Syncytial Virus Vaccine Candidate
Novavax CEO to Present at Piper Jaffray 20th Annual Healthcare Conference
Cleveland Clinic Recognizes New Strategies for Creating Vaccines for Avian Flu as a Top Ten Medical Innovation for 2009
Novavax CEO to Present at Lazard Capital Markets 5th Annual Healthcare Conference
Novavax Reports Third Quarter 2008 Financial Results
Novavax Announces Release Date of 2008 Third Quarter Financial Results and Investor Conference Call
Novavax CEO to Present at Oppenheimer 19th Annual Healthcare Conference
Novavax CEO to Present at BIO Investor Forum 2008
NOVAVAX Featured at Clinton Global Initiative 2008 Annual Meeting
NOVAVAX CEO to Present at 2008 UBS Global Life Sciences Conference
Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program
Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008
Novavax Reports Second Quarter 2008 Financial Results
Novavax CEO to Present at BMO Capital Markets Focus on Healthcare Conference
Novavax Announces Release Date of 2008 Second Quarter Financial Results and Investor Conference Call
Novavax Announces Closing of $18 Million Registered Direct Offering
Novavax Announces Pricing of $18 Million Financing of Common Stock and Warrants
Novavax to Join Russell 3000 Index
Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development - May 27 2008 1:02AM
Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial - May 27 2008 12:53AM
Novavax CEO to Present at ACUMENBioFin's 5th Annual Global Healthcare Conference - Jun 2 2008 12:29AM
Novavax Reports First Quarter 2008 Financial Results - Jun 2 2008 12:29AM
Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call - Jun 2 2008 12:28AM
Novavax Goes Through the Change as It Sheds Estrogen Drug to Focus on Vaccine Production, an Industrial Info News Alert - Jun 2 2008 12:28AM
Novavax Opens Its First U.S. Vaccine Plant - Jun 2 2008 12:28AM
Novavax CEO to Present at the World Vaccine Congress 2008
Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate